VIDEO: New options developing for treating anemia with myelofibrosis

ByDavid Statman

In this video, Ruben Mesa, MD, discussed the backstory behind a study presented at ASCO Annual Meeting, examining the effect of luspatercept on patients with myelofibrosis suffering from anemia.

Mesa, executive director of Atrium Health Wake Forest Baptist Comprehensive Cancer Center, discussed the results from the ACE-536-MF-001 study on luspatercept (Reblozyl; Celgene, Bristol Myers Squibb), which examined four cohorts of patients and found that the patients with the best anemia responses were transfusion dependent and on ruxolitinib (Jakafi, Incyte).

“I think the issue of anemia — which is one of the most frustrating and underserved areas — I think we’re going to have some options in the near future,” Mesa said.

Reference:

Gerds A, et al. Abstract 7016. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interview

Disclosures: Mesa reports consulting for AbbVie, Blueprint Medicines, Bristol Myers Squibb, CTI BioPharma, Genentech, Geron, GSK, Incyte, MorphoSys, Novartis, Sierra Oncology and Telios Pharma.

Take Homes in Myeloproliferative Neoplasms

Read more

VIDEO: New options developing for treating anemia with myelofibrosis

Reference:

Related Content